PUBLISHED ON: September 27, 2010 | Duration: 2 min, 06 sec
Glenmark has chosen to stay away from investing in diabetes research until it manages to find a partner as the cost of developing a cure for diabetes, said Glenn Saldanha, MD & CEO, Glenmark Pharma.
